Results 181 to 190 of about 188,791 (289)

Obinutuzumab Versus Rituximab for the Treatment of Primary Membranous Nephropathy: A Systematic Review and Meta-Analysis. [PDF]

Life (Basel)
Lurie A, Daneii P, Khan S, Khan Z, Mansuri H, Bizanti A.   +5 more
europepmc   +1 more source

Current Status of Kidney Xenotransplantation in Basic Research

Organ Medicine, EarlyView.
Kidney xenotransplantation is a potential solution to the organ shortage for end‐stage kidney disease. This review systematically elaborates on the application advances of donor pig gene editing technologies, the molecular mechanisms and regulatory strategies of xenogeneic immune rejection, and the optimization approaches of immune compatibility ...
Yu Luo, Bingzhuo Liu, Weijie Lai
wiley   +1 more source

Rapidly Progressive Cutaneous Nodules in an Elderly Woman

JEADV Clinical Practice, EarlyView.
Valeria Olvera‐Rodriguez, Gerardo González‐Martínez, Marion Carolina Alemán‐Jiménez, Minerva Gómez‐Flores, Jorge Ocampo‐Candiani, Lucía T. Fernández   +5 more
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Efficacy and safety of steroid-sparing strategy in the treatment of AIHA associated with KSHV/HHV-8 positive multicentric Castleman disease. [PDF]

Hemasphere
Dieudonné Y, Gourguechon C, Stammler R, Delestre F, Sorin B, Dunogué B, Dumas G, Fouquet G, Ronchetti AM, Paule R, Meliani P, Pansu N, Buzele R, Noel R, Fadlallah J, Malphettes M, Corvilain E, Meignin V, Guillaud C, Dossier A, Dion J, Gérard L, Oksenhendler E, Galicier L, Boutboul D.   +24 more
europepmc   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Refractory linear IgA dermatosis in childhood: a successful response to rituximab. [PDF]

An Bras Dermatol
Wakisaka PS, Lima Rodrigues LMC, Miyamoto D, Maruta CW, Santi CG, Aoki V.   +5 more
europepmc   +1 more source

Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis. [PDF]

Clin Cosmet Investig Dermatol
Alzahrani D, Niaz G, Roblah TM, Al-Osaimi AK, Alsulaimani H.   +4 more
europepmc   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source

Successful Treatment With Rituximab for Severe Immune Thrombocytopenic Purpura During Hemodialysis. [PDF]

Cureus
Hanyuda M, Wada Y, Motohashi T, Yanagisawa K, Saito G, Uchitsubo R, Kawamura S, Sakurabayashi S, Takeuchi K, Naito S, Takeuchi Y.   +10 more
europepmc   +1 more source